Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

Blesl, Andreas; Krones, Elisabeth; Pollheimer, Marion J; Haybaeck, Johannes; Wiesspeiner, Ulrike; Lipp, Rainer W; Kump, Patrizia

Blesl, Andreas; Krones, Elisabeth; Pollheimer, Marion J; Haybaeck, Johannes; Wiesspeiner, Ulrike; Lipp, Rainer W; Kump, Patrizia.

Afiliación

Blesl A; Clinical Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Krones E; Clinical Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Pollheimer MJ; Institute of Pathology, Medical University of Graz, Graz, Austria.
Haybaeck J; Institute of Pathology, Medical University of Graz, Graz, Austria.
Wiesspeiner U; Department of Pathology, Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Lipp RW; Clinical Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.
Kump P; Clinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Case Rep Oncol ; 10(3): 1121-1126, 2017.

Article en En | MEDLINE | ID: mdl-29430237

Palabras clave

Chemotherapy; Liver biopsy; Neuroendocrine tumor; Somatostatin; mTor

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Año: 2017 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google